2.Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. doi:10.1056/EVIDoa2200015 3.FDA approves durvalumab for locally advanced or metastatic biliary tract cancer. FDA. September 2, 2022. Accessed ...
cisplatin, and Nab-paclitaxel for resectable BTC.Methods:Resectable, treatment-nave BTC patients (pts) were enrolled and administered 3 cycles of neoadjuvant durvalumab (1000mg, iv, d1, q3w) + GAP (gemcitabine 1000mg/m2, cisplatin 25mg/m2, Nab-paclitaxel 100mg/m2, d1, d8, 21d cycle). ...
4 注射用培美曲塞二钠 英文名:Pemetrexed Disodium for Injection 商品名:力比泰 500mg/瓶,注射剂;剂量500mg/m2,静脉注射,每个周期(21天)第1天,共4-6个周期,或者直到确认PD 5 注射用盐酸吉西他滨 英文名:Gemcitabine 商品名:健择200mg或1g/支,注射剂;剂量1000或1250mg/m2 ,静脉注射,共4-6个周期,或者直到...
3. Oh D, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. doi:10.1056/EVIDoa2200015 (声明:文中图片来源于网络共享,如涉及侵权请联系作者删除处理)
5 注射用盐酸吉西他滨 英文名:Gemcitabine 商品名:健择200mg或1g/支,注射剂;剂量1000或1250mg/m2 ,静脉注射,共4-6个周期,或者直到确认PD 主要入排标准 入选标准 1 筛选时,年龄≥18岁。 2 在进行任何方案相关流程之前(包括PD-L1检测和其他...
5 注射用盐酸吉西他滨英文名:Gemcitabine 商品名:健择 200mg或1g/支,注射剂;剂量1000或1250mg/m2 ,静脉注射,共4-6个周期,或者直到确认PD 主要入排标准 入选标准 1 筛选时,年龄≥18岁。 2 在进行任何方案相关流程之前(包括PD-L1检测和其他筛选评估),从患者/法定代表获得书面知情同意。
The FDA has approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin in adult patients with locally advanced or metastatic biliary tract cancers.
药物类型 单克隆抗体 别名 Durvalumab (Genetical Recombination)、Durvalumab (genetical recombination) (JAN)、Durvalumab (USAN/INN) + [10] 靶点 PDL1 作用机制 PDL1抑制剂(程序性死亡配体1抑制剂) 治疗领域 肿瘤消化系统疾病呼吸系统疾病+ [12] 在研适应症 ...
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. doi:10.1056/EVIDoa2200015Recent Videos Survival Gains and Challenges: The CROSS Trial in GEJ Cancer The Lasting Impact of the CROSS Trial on GEJ Cancer Care Dostarlimab's Promise in...
Background:Immunotherapies have shown clinical activity in patients with advanced biliary tract cancer, for which outcomes remain poor despite standard of care treatment with gemcitabine and cisplatin. We aimed to evaluate gemcitabine and cisplatin plus durvalumab with or without tremelimumab as first-line...